I think we are much too early in the process to make that determination. Bid packet preparation, data room access etc. all take time. Give it 60 days. We will have our answer by then. I am still predicting an offer well north of these levels.
If I were them I would be more concerned about Elliot. Irritating someone who has the audacity/resources to stare down national governments is generally not a good tactic for one's long term survival.
He will....when the company is bought out. Evercore plus Elliot have a greater love of $$$$ then all (despite your nom de plume) and will get this done. Only a CHUMP would be against NUMP!
I am going to wait until Kingsbrook and their friends are done with this SH#T financing. UGHHHHHH....I hate it when these guys are involved. The funniest line in the agreement is where the "investors" agree not to short--either directly or indirectly. Yeah....sure. UGHHHHHHHHH!
US market of similar size to ROW but pricing will be much more favorable under U.S. reimbursement model (as it is for most drugs). QIDP adds to this value given additional period of exclusivity. Also, there is no Tauropharm to contend with on this side of the Atlantic. Finally, please talk to folks who manage catheters on a daily basis (I have). BTW, your soap and water ploy is disingenuous at best.
It is funny that the FDA would grant QIDP status to a soap and water substitute. You are a silly man----either misinformed yourself or intentionally misinforming others.
You miss my point, I was being sarcastic. LoveofMoney's ascertains are is silly. Data set on this product is stunning. It continues to track well(take a look @ London data from this weekend). Elliot wants it sold and Evercore has been engaged. The only thing we don't know is price and structure. (My guess is $$$$ plus approval CVR). Another round of legal jousting due i n July. i